D-0923-2017 Class III Terminated

Recalled by Noven Pharmaceuticals, Inc. — Miami, FL

FDA drug recall D-0923-2017 was initiated by Noven Pharmaceuticals, Inc. on Apr 27, 2017 and is designated Class III. Reason for recall: Defective Delivery System: Out of specification for peel force from the release liner specification during stability testing at 18M 25C/60%RH. The recall status is terminated (terminated Mar 11, 2019). Affected quantity: 14434 cartons.

Recall details

Product Type
Drugs
Report Date
Jul 5, 2017
Initiation Date
Apr 27, 2017
Termination Date
Mar 11, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14434 cartons

Product description

Minivelle (estradiol Transdermal System) 0.1 mg per day, pack of 8 systems per carton, Rx only, Dist. by: Noven Therapeutics, LLC. Miami, Florida 33186. NDC: 68968-6610-8

Reason for recall

Defective Delivery System: Out of specification for peel force from the release liner specification during stability testing at 18M 25C/60%RH.

Distribution pattern

Nationwide within US

Code information

Lot #:: 78618, Exp. 05/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0923-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0923-2017. Report a data issue: hello@regdatalab.com.